|
1 Ehrmann DA. Polycystic ovary syndrome. N Engl J Med,2005, 352:1223-1236.
|
|
2 Diamanti-Kandarakis E，Piperi C, Spina J, et al. Polycystic ovary syndrome：The influence of environmental and genetic factors. Hormones(Athens, Greece), 2006，5(1): 17-34.
|
|
3 Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome：Towards a rational approach. In: Dunaif A, Givens JR, Haseltine F，ed. Polycystic ovary syndrome. Boston：Blackwell Scientific, 1992，377-384.
|
|
4 Diamanti-Kandarakis E，Kouli CR，Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos：Hormonal and metabolic profile. J Clin Endocrinol Metab,1999,84(11):4006-4011.
|
|
5 Ehrmann DA, Liljenquist DR，Kasza K，et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2006，91：48-53.
|
|
6 Azziz R, Woods KS，Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab, 2004,89(6):2745-2749.
|
|
7 Legro RS, Myers ER，Barnhart HX, et al. Pregnancy in polycystic ovary syndrome(PCOS)baseline characteristics：Effect of race and ethnicity on the PCOS phenotype. J Soc Gynecol Investig, 2006,13：268a-269a.
|
|
8 Watson RT，Pessin JE. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Hormone Res,2001，56:175-193.
|
|
9 Ricardo A, Enrico C, Dider D，et al. Position Statement：Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome：An androgen excess society guideline. J Clin Endocrinol Metab, 2006, 91(11)：4237-4245.
|
|
10 Wu XK，Pollanen P，Erkkola R. Selective ovarian resistance to insulin signaling in women with polycystic ovary syndrome. Fertil Steril，2003，80：264-277.
|
|
11 The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril,2004, 81(1)：19-25.
|
|
12 Franks S，Mason H，White D，et al. Etiology of anovulation in polycystic ovary syndrome. Steroids,1998，63: 306-307.
|
|
13 Carmina E，Rosato F，Janni A, et al. Extensive clinical experience：Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab, 2006，91：2-6.
|
|
14 Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab, 1996, 81:942-947.
|
|
15 Wang Y, Fan HJ, Wu XK, et al. Genetic polymorphism of CYP19∆3(TTTA)nallele in Chinese women. Chin J Public Health,2005,21(5)：539-540.
|
|
16 Fan HJ, Wang Y, Wu XK, et al. Genetic polymorphism of CYP11α(tttta)n allele in Chinese women. Chin J Public Health, 2006,22(2)：221-222.
|
|
17 Mansfield R, Galea R, Brincat M, et al. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril, 2003，79: 956-962.
|
|
18 Nelson VL，Legro RS，Strauss JF 3rd，et al. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol,1999，13:946-957.
|
|
19 Escobar-Morreale HF, Luque-Ramirez M，San-Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev, 2005，26：251-282.
|
|
20 Wood JR, Ho CK，Nelson-Degrave VL, et al. The molecular signature of polycystic ovary syndrome(PCOS)theca cells defined by gene expression profiling. J Reprod Immunol，2004，63: 51-60.
|
|
21 Mitwally MF，Witchel SF, Casper RF. Troglitazone：A possible modulator of ovarian steroidogenesis. J Soc Gynecol Investig, 2002，9: 163-167.
|
|
22 Stadtmauer LA, Toma SK, Rieh1 RM, et al. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril,2001，75: 505-509.
|
|
23 Mifsud A, Ramirez S，Yong EL. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metab,2000, 85：3484-3488.
|
|
24 Robert JN, Didier D, Richard SL, et al. Polycystic ovary syndrome. Lancet, 2007, 370:685-697.
|
|
25 Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med,2001，111：607-613.
|
|
26 Kelly CC，Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab, 2001，86：2453-2455.
|
|
27 Knowler WC, Barrett-Connor E，Fowler SE，et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002，346：393-403.
|
|
28 Stamets K, Taylor DS，Kunselman A, et al. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril,2004, 81: 630-637.
|
|
29 Ellis JA，Sinclair R, Harrap SB. Androgenetic alopecia：Pathogenesis and potential for therapy. Expert Rev Mol Med,2002,(3)：1-11.
|
|
30 Lucky AW, Piacquadio DJ，Ditre CM，et al. A randomized,placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol,2004，50: 541-553.
|